Tirzepatide vs Orforglipron
A dual agonist injection versus a single-hormone oral pill. Tirzepatide is Zepbound/Mounjaro (Eli Lilly). Orforglipron is Foundayo (also Eli Lilly). Both are highly effective, but they offer different trade-offs.
Quick read · 5 min
The core trade-off: tirzepatide produces significantly higher weight loss through its unique dual-hormone mechanism, but requires a weekly injection and costs more. Orforglipron offers a daily pill with no food restrictions and lower cost, but produces lower weight loss.
- •Tirzepatide: 20.9% weight loss (dual agonist), once-weekly injection, ~$1,086/month
- •Orforglipron: 12.4% weight loss (GLP-1 only), daily pill, no food restrictions, ~$149–$349/month
- •Tirzepatide produces roughly 20 lbs more weight loss for a 240 lb person
- •Orforglipron is ideal for people with injection anxiety or busy schedules
- •Both made by Eli Lilly. No head-to-head trial — this is an indirect comparison.
No Head-to-Head Trial
There is no clinical trial directly comparing tirzepatide injection with orforglipron. Tirzepatide data comes from SURMOUNT-1 (Eli Lilly). Orforglipron data comes from ATTAIN-1 and ATTAIN-2 (also Eli Lilly). The comparison below uses data from these separate studies, which is less definitive than a head-to-head trial.
Weight Loss Comparison
Context: Tirzepatide shows substantially higher weight loss — roughly 20 lbs more for a 240 lb person. This 8.5 percentage point difference is significant and reflects tirzepatide's dual-hormone mechanism. Individual results vary substantially.
How They Work Differently
Tirzepatide (dual agonist)
Activates two hunger signals in the brain: GIP and GLP-1. Researchers believe that activating both together produces greater appetite reduction and weight loss than activating either one alone. This is why tirzepatide is more potent than GLP-1-only drugs.
Orforglipron (GLP-1 only)
Activates one hunger signal: GLP-1 only. This is the same mechanism as semaglutide, liraglutide, and other GLP-1 drugs. Effective, but less potent than dual agonists.
Implication: If maximum weight loss is your priority, tirzepatide's dual mechanism gives a measurable advantage. If convenience and affordability matter more, orforglipron is still highly effective.
Form and Convenience
Tirzepatide
Once-weekly subcutaneous injection (you inject under the skin once per week). No food timing restrictions. Requires dose escalation over several months.
Orforglipron
Once-daily oral tablet. Take anytime, no food restrictions. Requires dose escalation over several months (similar timeline to tirzepatide).
Implication: Tirzepatide requires weekly injections but no timing considerations. Orforglipron is daily but no injection anxiety. Choose based on your needle comfort and daily routine.
Cost Comparison
Major difference: Orforglipron is 6–7 times cheaper than tirzepatide self-pay. With insurance, both are comparable.
Side Effect Comparison
Both drugs
Nausea is most common (31–33% in trials), typically in the first 4–8 weeks, then subsides. Other GI side effects (diarrhea, constipation, vomiting) also common.
Tirzepatide
Slightly higher rates of nausea and diarrhea in trials. This may be related to the dual-hormone mechanism. Side effect severity varies widely by individual.
Orforglipron
Similar side effect profile to other GLP-1 drugs. Slightly lower nausea rates than tirzepatide, but this is indirect comparison data.
Context: Side effect severity varies widely by individual. Neither profile is dramatically different from the other.
Trade-Off Summary
Tirzepatide Profile
- ✓Highest weight loss among approved drugs (20.9%)
- ✓Unique dual-hormone mechanism (GIP + GLP-1)
- ✓Once-weekly dosing (only 4 injections/month)
- ◆Weekly injections (may be difficult for injection-anxious patients)
- ◆Much higher cost (~$1,086/month vs $149–$349/month)
- ◆Slightly higher nausea rates in early weeks
Orforglipron Profile
- ✓Daily pill — no injection anxiety
- ✓Zero food timing restrictions — take anytime
- ✓Much lower cost (~$149–$349/month self-pay)
- ✓First small-molecule GLP-1 (novel technology)
- ◆Substantially lower weight loss (12.4% vs 20.9%)
- ◆GLP-1 only mechanism (not dual like tirzepatide)
- ◆Newer — less long-term follow-up data
These two drugs differ substantially in weight loss, mechanism, form, and cost. Tirzepatide is the more potent option for maximum weight loss. Orforglipron is the more convenient and affordable option. Neither is universally "better" — they suit different priorities. A doctor can help you decide based on your tolerance for injections, cost sensitivity, and target weight loss.
Common Questions
Not sure where to start? Our 2-minute quiz can help.
Take the quiz →Based on clinical trials · No rankings · Every claim linked to source
Last reviewed: March 2026